Beneficial effects of anti-apolipoprotein A-2 on an animal model for coronary arteritis in Kawasaki disease
Abstract Background Kawasaki disease (KD) is usually treated with high-dose intravenous immunoglobulin (IVIg) as severe infectious and other diseases. Due to issues that are associated with immunoglobulin preparation, such as the risk of possible contamination by infectious agents and limited blood...
Saved in:
Main Authors: | Fuyu Ito (Author), Toshiaki Oharaseki (Author), Daisuke Tsukui (Author), Yoshitaka Kimura (Author), Tamiko Yanagida (Author), Fukuko Kishi (Author), Yoshio Yamakawa (Author), Yosuke Kameoka (Author), Shoichi Suzuki (Author), Kazuko Uno (Author), Osamu Suzuki (Author), Noriko N. Miura (Author), Naohito Ohno (Author), Kei Takahashi (Author), Hajime Kono (Author), Kazuo Suzuki (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease
by: Ohno Naohito, et al.
Published: (2011) -
Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis
by: Kameoka Y, et al.
Published: (2019) -
Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis [Corrigendum]
by: Kameoka Y, et al.
Published: (2019) -
Vasculitis and crescentic glomerulonephritis in a newly established congenic mouse strain derived from ANCA-associated vasculitis-prone SCG/Kj mice
by: Yoshitomo Hamano, et al.
Published: (2019) -
Development of an apolipoprotein E mimetic peptide-lipid conjugate for efficient brain delivery of liposomes
by: Naoya Kato, et al.
Published: (2023)